Technology ID
TAB-1817

Prevention and Treatment of Multiple Sclerosis (MS) by Administering E-Selectin

E-Numbers
E-153-2005-0
E-153-2005-2
Lead Inventor
Shukaliak-Quandt, Jacqueline (NINDS)
Applications
Therapeutics
Therapeutic Areas
Neurology
Development Stages
Pre-Clinical (in vitro)
Development Status
In vitro and in vivo data are available.
ICs
NINDS
The invention is a method and composition for inhibiting or treating symptoms of inflammatory demyelination or inflammation associated with autoimmune disorders. This is accomplished by administering recombinant E-selectin protein intranasally and resulting in E selectin-specific regulatory T-cells. These regulatory T-cells suppress activation of blood vessels where E-selectin is normally expressed by the localized production of immunosuppressive cytokines, modulating the actions of otherwise pro-inflammatory T cells that can aberrantly cause demyelination of neurons, which leads to diseases like MS.
Commercial Applications
In addition to MS, potentially effective in treating other autoimmune disorders such as rheumatoid arthritis, type 1 diabetes, psoriasis, and those that affect blood vessels.

Licensing Contact:
Specialist (ALS), Admin. Licensing
nihott@nih.gov